| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10e4b1416c6e66e0ade5429212414964 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4082
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4839
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J7-0076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2015-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be0247e3e938b99fb9e013404b9dfaa2 |
| publicationDate |
2017-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20170005434-A |
| titleOfInvention |
Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| abstract |
The present invention is directed to a method of treating or reducing gait degeneration in a human patient diagnosed with a high baseline disorder score that is associated with relapse-relieved multiple sclerosis (RRMS) and which complies with the Kurtzche Expanded Disability State Scale (EDSS) Comprising periodically administering to a patient diagnosed with having a high baseline-score of failure only a predetermined amount of raquinÃmode effective to treat the patient or to reduce gait degeneration. The present invention further provides pharmaceutical compositions and packages diagnosed as suffering from RRMS and comprising an effective amount of a rquidney mode for treating a human patient with a high baseline score according to EDSS. |
| priorityDate |
2014-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |